Document:

EX-10.16

 Exhibit 10.16 
  

 
 6400 Westwind Way, Suite A 

Crestwood, KY, 40014 
 P:(502)
241-4114 
 October 9, 2017 

Mr. Timothy Sullivan 
 VIA EMAIL 

Dear Tim, 
 We are pleased to extend you an offer to join
Apellis Pharmaceuticals, Inc. (the “Company”) as its Chief Financial Officer on the terms and conditions set forth in this letter. Subject to satisfaction of the conditions described in this letter, you will begin employment on Monday,
October 16, 2017 (or another mutually acceptable start date) (the “Start Date”). You agree to devote your full business time, attention and best efforts to the performance of your duties and to the furtherance of the Company’s
interests, and shall not engage in any other employment, consulting or other business activity without the prior written consent of the Company. Any exceptions must be first approved in writing by the Chief Executive Officer after consultation with
the Board of Directors. 
 You will primarily work from our offices in Cambridge and Waltham, Massachusetts, with such additional travel as may be
reasonably required from time to time to properly fulfill your employment duties and responsibilities. You will report to the Chief Executive Officer. Your job responsibilities will include defining the overall financial strategy for Apellis and
oversight and execution of financing and corporate transactions, budgeting, audits and related matters and such other responsibilities as may be delegated to you by the Chief Executive Officer, all as may be modified from time to time by the Chief
Executive Officer. 
 Your initial salary will be $27,083 per month, equivalent to an annualized base salary of $325,000, paid in accordance with our
standard payroll practices and subject to all withholdings and deductions as required by law, for your full-time efforts, of at least 40 hours per week. Your base salary will be subject to adjustment as determined by the Board of Directors in its
sole discretion. You will also be eligible for annual bonus compensation of up to 20% of your annualized base salary, based upon company, departmental and individual performance against the applicable performance goals established by the Board of
Directors. For 2017, you will receive a pro-rated annual bonus based on the number of 

 
days you are employed during the year. You must remain continuously employed with the Company through the date of the bonus payment to receive such payment. All bonus payments, if any, are
subject to the approval of the Board of Directors in its sole discretion. 
 You will be eligible for Apellis’ standard benefits package offered to
every full-time employee, which currently includes health insurance, LTD/ADD/life insurance, and 401(k), provided that you are eligible under, and subject to all provisions of, the plan documents that govern those programs. You will be reimbursed
for reasonable travel and other expenses incurred by you in performing your services to the Company in accordance with our reimbursement policy. You will be entitled to 20 days paid time off (PTO) for vacation, illness or personal business each full
calendar year (i.e., accruing at the rate of 13.33 hours per month) in accordance with our PTO policy. Apellis reserves the right to amend, modify or terminate any of its benefit plans, policies or programs at any time and for any reason. 

Subject to the approval of the Board of Directors, you will receive an option to purchase 850,000 shares of Common Stock (representing approximately 0.9% of
the fully-diluted common stock equivalents as of the date hereof), at an exercise price equal to the fair market value as determined by the Board of Directors at the time of the grant, with such option to vest as to 25% of the underlying shares on
the first anniversary of the Start Date and to vest as to the balance in equal monthly installments of 2.08% thereafter until the fourth anniversary of the Start Date. The vesting of this option will commence as of the Start Date, and will
accelerate upon a Change of Control Event (as defined in the 2010 Equity Incentive Plan) with respect to 100% of the unvested shares underlying the option. 

All forms of compensation paid to you as an employee shall be less all applicable withholdings. 

On your first day of employment, you will be given additional information about our procedures, policies, benefit programs and more. We will require you, as
conditions of employment, to verify your right to work in the United States and to enter into the standard noncompetition, nondisclosure and development agreement on your first day of employment and to provide proof of your eligibility to work in
the United States. 
 By signing below, you represent that (i) your employment with the Company and this offer letter does not and will not violate or
conflict with any obligations you may have to or any agreements you may have with any former employer and (ii) you have provided the Company with all written agreements that describe any continuing post-employment obligations to any former
employer. 

 Your employment will be at-will, and this letter does not represent any
guarantee of employment for any period. If you wish to resign from your employment with the Company, we request not less than 15 calendar days’ written notice. 

This offer letter, along with the option agreement and the noncompetition, nondisclosure and development agreement, constitute the complete agreement between
you and the Company, contain all the terms of your employment, and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. The terms of this offer letter and the resolution of
any disputes as to the meaning, effect, performance or validity of this offer letter or arising out of, related to, or in any way connected with, this offer letter, your employment with the Company or any other relationship between you and the
Company (the “Disputes”) will be governed by Massachusetts law, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the
Commonwealth of Massachusetts in connection with any Dispute or any claim related to any Dispute. 
 We are excited at the prospect of your joining our
team. If this letter correctly sets forth the terms under which you will be employed by the Company, please sign the enclosed duplicate of this letter in the space provided below and return it to me. If you do not accept this offer by
October 16, 2017, this offer will be deemed revoked. Please let me know if you have any questions. 
  

	
	 Sincerely,

	
	 /s/ Cedric Francois

	
	 Cedric Francois, M.D., Ph.D.

	 Chief Executive Officer

	 Apellis Pharmaceuticals Inc.

  

	
	ACCEPTED AND AGREED:
	
	 /s/ Timothy Sullivan

	Name: Timothy Sullivan
	Date: October 9, 2017EX-10.17

 Exhibit 10.17 

THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS 

EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON 

TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT AND TO 

CERTAIN FURTHER RESTRICTIONS SET FORTH IN A RIGHT OF FIRST 

REFUSAL AND CO-SALE AGREEMENT BY AND AMONG THE COMPANY AND 

CERTAIN OTHER HOLDERS OF THE COMPANY’S STOCK 
  

			
	Warrant No. 1	  	 Number of Shares: 200,000

(subject to adjustment)

	Date of Issuance: October 19, 2017	  	

 Original Issue Date (as defined in subsection 

2(a)): October 19, 2017 
 Apellis
Pharmaceuticals, Inc. 
 Common Stock Purchase Warrant 

(Void after October 19, 2018) 

Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that Golda Darty
Partners, S.A., or its registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, 200,000 shares of Common Stock, $0.0001 par value per share, of the
Company (“Common Stock”), at a purchase price of $2.571 per share, at any time or from time to time on or after the date of issuance and on or before the earliest of: (i) 5:00 p.m. (Boston time) on October 19, 2018; (ii) the
closing date of a “Deemed Liquidation Event” as defined in the Company’s Certificate of Incorporation, as amended and restated (the “Charter”); and (iii) the closing date of a “Qualified Public Offering” as
defined in the Charter. The shares purchasable upon exercise of this Warrant, and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant
Shares” and the “Purchase Price,” respectively. This Warrant is issued in consideration of the Loan made to the Company by the Registered Holder under the Promissory Note dated October 19, 2017. 

1.    Exercise. 

(a)    Exercise for Cash. The Registered Holder may, at his option, elect to exercise this Warrant, in whole or in
part and at any time or from time to time, by surrendering this Warrant, with the purchase form appended hereto as Exhibit I duly executed by or on behalf of the Registered Holder, at the principal office of the Company, or
at such other office or agency as the Company may designate, accompanied by payment in full, in lawful money of the United States, of the Purchase Price payable in respect of the number of Warrant Shares purchased upon such exercise. 

 (b)    Exercise Date. Each exercise of this Warrant shall be deemed to
have been effected immediately prior to the close of business on the day on which this Warrant shall have been surrendered to the Company as provided in subsection 1(a) above (the “Exercise Date”). At such time, the person or persons in
whose name or names any certificates for Warrant Shares shall be issuable upon such exercise as provided in subsection 1(c) below shall be deemed to have become the holder or holders of record of the Warrant Shares represented by such certificates.

 (c)    Issuance of Certificates. As soon as practicable after the exercise of this Warrant in whole or in
part, and in any event within 10 days thereafter, the Company, at its expense, will cause to be issued in the name of, and delivered to, the Registered Holder, or as the Registered Holder (upon payment by the Registered Holder of any applicable
transfer taxes) may direct: 
 (i)    a certificate or certificates for the number of full Warrant Shares to which the
Registered Holder shall be entitled upon such exercise plus, in lieu of any fractional share to which the Registered Holder would otherwise be entitled, cash in an amount determined pursuant to Section 3 hereof; and 

(ii)    in case such exercise is in part only, a new warrant or warrants (dated the date hereof) of like tenor, calling
in the aggregate on the face or faces thereof for the number of Warrant Shares equal (without giving effect to any adjustment therein) to the number of such shares called for on the face of this Warrant minus the number of Warrant Shares for which
this Warrant was so exercised. 
 2.    Adjustments. 

(a)    Adjustment for Stock Splits and Combinations. If the Company shall at any time or from time to time after
the date on which this Warrant was first issued (or, if this Warrant was issued upon partial exercise of, or in replacement of, another warrant of like tenor, then the date on which such original warrant was first issued) (either such date being
referred to as the “Original Issue Date”) effect a subdivision of the outstanding Common Stock, the Purchase Price then in effect immediately before that subdivision shall be proportionately decreased. If the Company shall at any time or
from time to time after the Original Issue Date combine the outstanding shares of Common Stock, the Purchase Price then in effect immediately before the combination shall be proportionately increased. Any adjustment under this paragraph shall become
effective at the close of business on the date the subdivision or combination becomes effective. 
 (b)    Adjustment
for Certain Dividends and Distributions. In the event the Company at any time, or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a
dividend or other distribution payable in additional shares of Common Stock, then and in each such event the Purchase Price then in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a
record date shall have been fixed, as of the close of business on such record date, by multiplying the Purchase Price then in effect by a fraction: 

  
 -2- 

 (1)    the numerator of which shall be the total number of shares of Common
Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date, and 

(2)    the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately
prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution; 

provided, however, that if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made
on the date fixed therefor, the Purchase Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Purchase Price shall be adjusted pursuant to this paragraph as of the time of actual payment of such
dividends or distributions. 
 (c)    Adjustment in Number of Warrant Shares. When any adjustment is required to
be made in the Purchase Price pursuant to subsections 2(a) or 2(b), the number of Warrant Shares purchasable upon the exercise of this Warrant shall be changed to the number determined by dividing (i) an amount equal to the number of
shares issuable upon the exercise of this Warrant immediately prior to such adjustment, multiplied by the Purchase Price in effect immediately prior to such adjustment, by (ii) the Purchase Price in effect immediately after such adjustment.

 (d)    Adjustments for Other Dividends and Distributions. In the event the Company at any time or from time to
time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Company (other than shares of Common
Stock) or in cash or other property (other than regular cash dividends paid out of earnings or earned surplus, determined in accordance with generally accepted accounting principles), then and in each such event provision shall be made so that the
Registered Holder shall receive upon exercise hereof, in addition to the number of shares of Common Stock issuable hereunder, the kind and amount of securities of the Company, cash or other property which the Registered Holder would have been
entitled to receive had this Warrant been exercised on the date of such event and had the Registered Holder thereafter, during the period from the date of such event to and including the Exercise Date, retained any such securities receivable during
such period, giving application to all adjustments called for during such period under this Section 2 with respect to the rights of the Registered Holder.  

(e)    Adjustment for Reorganization. If there shall occur any reorganization, recapitalization, reclassification,
consolidation or merger involving the Company in which the Common Stock is converted into or exchanged for securities, cash or other property (other than a transaction covered by subsections 2(a), 2(b) or 2(d)) (collectively, a
“Reorganization”), then, following such Reorganization, the Registered Holder shall receive upon exercise hereof the kind and amount of securities, cash or other property which the Registered Holder would have been entitled to receive
pursuant to such Reorganization if such exercise had taken place immediately prior to such Reorganization. In any such case, appropriate adjustment (as determined in good faith by the Board) shall be made in the application of the provisions set
forth herein with respect to the rights and interests thereafter of the Registered Holder, to the end that the provisions set forth in this Section 2 (including provisions with respect to changes in and other adjustments of the Purchase Price)
shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities, cash or other property thereafter deliverable upon the exercise of this Warrant. 

  
 -3- 

 (f)    Certificate as to Adjustments. Upon the occurrence of each
adjustment or readjustment of the Purchase Price pursuant to this Section 2, the Company at its expense shall, as promptly as reasonably practicable but in any event not later than 10 days thereafter, compute such adjustment or readjustment in
accordance with the terms hereof and furnish to the Registered Holder a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property for which this Warrant shall be exercisable and
the Purchase Price) and showing in detail the facts upon which such adjustment or readjustment is based. The Company shall, as promptly as reasonably practicable after the written request at any time of the Registered Holder (but in any event not
later than 10 days thereafter), furnish or cause to be furnished to the Registered Holder a certificate setting forth (i) the Purchase Price then in effect and (ii) the number of shares of Common Stock and the amount, if any, of other
securities, cash or property which then would be received upon the exercise of this Warrant. 
 3.    Fractional
Shares. 
 (a)    The Company shall not be required upon the exercise of this Warrant to issue any fractional
shares, but shall pay the value thereof to the Registered Holder in cash on the basis of the Fair Market Value per share of Common Stock, as determined pursuant to subsection 3(b) below. 

(b)    The Fair Market Value per share of Common Stock shall be determined as follows: 

(i)    If the Common Stock is listed on a national securities exchange or another nationally recognized trading system as
of the Exercise Date, the Fair Market Value per share of Common Stock shall be deemed to be the average of the high and low reported sale prices per share of Common Stock thereon on the trading day immediately preceding the Exercise Date
(provided that if no such price is reported on such day, the Fair Market Value per share of Common Stock shall be determined pursuant to clause (ii)). 

(ii)    If the Common Stock is not listed on a national securities exchange, the Nasdaq National Market or another
nationally recognized trading system as of the Exercise Date, the Fair Market Value per share of Common Stock shall be deemed to be the amount most recently determined by the Board of Directors of the Company (the “Board”) to represent the
fair market value per share of the Common Stock (including without limitation a determination for purposes of granting Common Stock options or issuing Common Stock under any plan, agreement or arrangement with employees of the Company); and, upon
request of the Registered Holder, the Board (or a representative thereof) shall, as promptly as reasonably practicable but in any event not later than 10 days after such request, notify the Registered Holder of the Fair Market Value per share of
Common Stock and furnish the Registered Holder with reasonable documentation of the Board’s determination of such Fair Market Value. Notwithstanding the foregoing, if the Board has not made such a determination within the three-month period
prior to the Exercise Date, then (A) the Board shall make, and shall provide or cause to be provided to the Registered Holder notice of, a determination of the Fair Market Value per share of the Common Stock within 15 days of a request by the
Registered Holder that it do so, and (B) the exercise of this Warrant shall be delayed until such determination is made and notice thereof is provided to the Registered Holder. 

  
 -4- 

 4.    Investment Representations. The initial Registered Holder
represents and warrants to the Company as follows: 
 (a)    Investment. The Registered Holder is acquiring the
Warrant, and (if and when he exercises this Warrant) he will acquire the Warrant Shares, for his own account for investment and not with a view to, or for sale in connection with, any distribution thereof, nor with any present intention of
distributing or selling the same; and the Registered Holder has no present or contemplated agreement, undertaking, arrangement, obligation, indebtedness or commitment providing for the disposition thereof. 

(b)    Accredited Investor. The Registered Holder is an “accredited investor” as defined in Rule 501(a)
under the Securities Act of 1933, as amended (the “Act”). 
 (c)    Experience. The Registered Holder
has made such inquiry concerning the Company and its business and personnel as he has deemed appropriate; and the Registered Holder has sufficient knowledge and experience in finance and business that he is capable of evaluating the risks and merits
of his investment in the Company. 
 5.    Transfers, etc. 

(a)    This Warrant and the Warrant Shares shall not be sold or transferred unless either (i) they first shall have
been registered under the Act, or (ii) the Company first shall have been furnished with an opinion of legal counsel, reasonably satisfactory to the Company, to the effect that such sale or transfer is exempt from the registration requirements
of the Act. Notwithstanding the foregoing, no registration or opinion of counsel shall be required for (i) a transfer by a Registered Holder which is an entity to a wholly owned subsidiary of such entity, a transfer by a Registered Holder which
is a partnership to a partner of such partnership or a retired partner of such partnership or to the estate of any such partner or retired partner, or a transfer by a Registered Holder which is a limited liability company to a member of such limited
liability company or a retired member or to the estate of any such member or retired member, provided that the transferee in each case agrees in writing to be subject to the terms of this Section 5, or (ii) a transfer made in
accordance with Rule 144 under the Act. 
 (b)    Each certificate representing Warrant Shares shall bear a legend
substantially in the following form: 
 “The securities represented by this certificate have not been registered under the Securities
Act of 1933, as amended, and may not be offered, sold or otherwise transferred, pledged or hypothecated unless and until such securities are registered under such Act or an opinion of counsel satisfactory to the Company is obtained to the effect
that such registration is not required.” 

  
 -5- 

 The foregoing legend shall be removed from the certificates representing any Warrant Shares, at
the request of the holder thereof, at such time as (i) a period of at least one year, as determined in accordance with paragraph (d) of Rule 144 under the Act, has elapsed since the later of the date the Warrant Shares were acquired from
the Company or an affiliate of the Company, and (ii) the Warrant Shares become eligible for resale pursuant to Rule 144(b)(1)(i) under the Act. 

(c)    The Company will maintain a register containing the name and address of the Registered Holder of this Warrant. The
Registered Holder may change his address as shown on the warrant register by written notice to the Company requesting such change. 

(d)    Subject to the provisions of Section 5 hereof, this Warrant and all rights hereunder are transferable, in
whole or in part, upon surrender of this Warrant with a properly executed assignment (in the form of Exhibit II hereto) at the principal office of the Company (or, if another office or agency has been designated by the
Company for such purpose, then at such other office or agency). 
 6.    Notices of Record Date, etc. In the
event: 
 (a)    the Company shall take a record of the holders of its Common Stock (or other stock or securities at the
time deliverable upon the exercise of this Warrant) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of stock of any class or any other
securities, or to receive any other right; or 
 (b)    of any capital reorganization of the Company, any
reclassification of the Common Stock of the Company, any consolidation or merger of the Company with or into another corporation, or any transfer of all or substantially all of the assets of the Company; or 

(c)    of the voluntary or involuntary dissolution, liquidation or winding-up of
the Company, 
 then, and in each such case, the Company will send or cause to be sent to the Registered Holder a notice specifying, as the case may be,
(i) the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii) the effective date on which such reorganization, reclassification, consolidation, merger, transfer,
dissolution, liquidation or winding-up is to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other stock or securities at the time deliverable upon
the exercise of this Warrant) shall be entitled to exchange their shares of Common Stock (or such other stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer,
dissolution, liquidation or winding-up. Such notice shall be sent at least 10 days prior to the record date or effective date for the event specified in such notice. 

7.    Reservation of Stock. The Company will at all times reserve and keep available, solely for issuance and
delivery upon the exercise of this Warrant, such number of Warrant Shares and other securities, cash and/or property, as from time to time shall be issuable upon the exercise of this Warrant. 

  
 -6- 

 8.    Exchange or Replacement of Warrants. 

(a)    Upon the surrender by the Registered Holder, properly endorsed, to the Company at the principal office of the
Company, the Company will, subject to the provisions of Section 5 hereof, issue and deliver to or upon the order of the Registered Holder, at the Company’s expense, a new Warrant or Warrants of like tenor, in the name of the Registered
Holder or as the Registered Holder (upon payment by the Registered Holder of any applicable transfer taxes) may direct, calling in the aggregate on the face or faces thereof for the number of shares of Common Stock (or other securities, cash and/or
property) then issuable upon exercise of this Warrant. 
 (b)    Upon receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably required) in an amount reasonably satisfactory to the Company,
or (in the case of mutilation) upon surrender and cancellation of this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor. 

9.    Agreement in Connection with Public Offering. The Registered Holder agrees, in connection with the initial
underwritten public offering of the Company’s securities pursuant to a registration statement under the Act, (i) not to sell, make short sale of, loan, grant any options for the purchase of, or otherwise dispose of any shares of Common
Stock held by the Registered Holder (other than any shares included in the offering) without the prior written consent of the Company or the underwriters managing such initial underwritten public offering of the Company’s securities for a
period of 180 days from the effective date of such registration statement (which period may be extended upon the request of the managing underwriter, to the extent required by any NASD or FINRA rules, for an additional period of up to 18 days if the
Company issues or proposes to issue an earnings or other public release within 18 days of the expiration of the 180-day lockup period), and (ii) to execute any agreement reflecting clause (i) above
as may be requested by the Company or the managing underwriters at the time of such offering. 
 10.    Notices.
All notices and other communications from the Company to the Registered Holder in connection herewith shall be mailed by certified or registered mail, postage prepaid, or sent via a reputable nationwide overnight courier service guaranteeing next
business day delivery, to the address last furnished to the Company in writing by the Registered Holder. All notices and other communications from the Registered Holder to the Company in connection herewith shall be mailed by certified or registered
mail, postage prepaid, or sent via a reputable nationwide overnight courier service guaranteeing next business day delivery, to the Company at its principal office set forth below. If the Company should at any time change the location of its
principal office to a place other than as set forth below, it shall give prompt written notice to the Registered Holder and thereafter all references in this Warrant to the location of its principal office at the particular time shall be as so
specified in such notice. All such notices and communications shall be deemed delivered (i) two business days after being sent by certified or registered mail, return receipt requested, postage prepaid, or (ii) one business day after being
sent via a reputable nationwide overnight courier service guaranteeing next business day delivery. 

  
 -7- 

 11.    No Rights as Stockholder. Until the exercise of this Warrant,
the Registered Holder shall not have or exercise any rights by virtue hereof as a stockholder of the Company. Notwithstanding the foregoing, in the event (i) the Company effects a split of the Common Stock by means of a stock dividend and the
Purchase Price of and the number of Warrant Shares are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), and (ii) the Registered Holder exercises this Warrant between the record
date and the distribution date for such stock dividend, the Registered Holder shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such exercise, notwithstanding the fact
that such shares were not outstanding as of the close of business on the record date for such stock dividend. 

12.    Amendment or Waiver. Any term of this Warrant may be amended or waived only by an instrument in writing
signed by the party against which enforcement of the change or waiver is sought. No waivers of any term, condition or provision of this Warrant, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of
any such term, condition or provision. 
 13.    Section Headings. The section headings in this Warrant are for
the convenience of the parties and in no way alter, modify, amend, limit or restrict the contractual obligations of the parties. 

14.    Governing Law. This Warrant will be governed by and construed in accordance with the internal laws of
Delaware (without reference to the conflicts of law provisions thereof). 
 15.    Facsimile Signatures. This
Warrant may be executed by facsimile signature. 
 EXECUTED as of the Date of Issuance indicated above. 

 

			
	Apellis Pharmaceuticals, Inc.
	
	 /s/ Nicole Perry

	By:	 	Nicole Perry
	Title:	 	Vice President of Finance

  
 -8- 

 EXHIBIT I 

PURCHASE FORM 
  

			
	To:                                 	  	Dated:                                 

 The undersigned, pursuant to the provisions set forth in the attached Warrant
(No.         ), hereby elects to purchase          shares of the Common Stock of Apellis Pharmaceuticals, Inc. covered by such Warrant. 

The undersigned herewith makes payment of
$                     in lawful money of the United States, which constitutes the full purchase price for such shares at the price per share
provided for in such Warrant. 
  

			
	 Signature:
	 	  

		
	 Address:
	 	  

		
		 	  

  
 -9- 

 EXHIBIT II 

ASSIGNMENT FORM 
 FOR VALUE
RECEIVED,
                                         
                                         
   hereby sells, assigns and transfers all of the rights of the undersigned under the attached Warrant (No.             ) with respect to the number of shares of Common
Stock of Apellis Pharmaceuticals, Inc. covered thereby set forth below, unto: 
  

					
	Name of Assignee	  	Address	  	No. of Shares

  

			
	Dated:
                                         
               	  	Signature:
                                         
               

 Signature Guaranteed: 
 By:
                                         
                    
 The signature should be guaranteed
by an eligible guarantor institution (banks, stockbrokers, savings and loan associations and credit unions with membership in an approved signature guarantee medallion program) pursuant to Rule 17Ad-15
under the Securities Exchange Act of 1934. 

  
 -10-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]